194 related articles for article (PubMed ID: 30712135)
1. A possible biomarker of neurocytolysis in infantile gangliosidoses: aspartate transaminase.
Kılıç M; Kasapkara ÇS; Kılavuz S; Mungan NÖ; Biberoğlu G
Metab Brain Dis; 2019 Apr; 34(2):495-503. PubMed ID: 30712135
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
Jeyakumar M; Thomas R; Elliot-Smith E; Smith DA; van der Spoel AC; d'Azzo A; Perry VH; Butters TD; Dwek RA; Platt FM
Brain; 2003 Apr; 126(Pt 4):974-87. PubMed ID: 12615653
[TBL] [Abstract][Full Text] [Related]
3. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
Nestrasil I; Ahmed A; Utz JM; Rudser K; Whitley CB; Jarnes-Utz JR
Mol Genet Metab; 2018 Feb; 123(2):97-104. PubMed ID: 29352662
[TBL] [Abstract][Full Text] [Related]
4. Infantile gangliosidoses: Mapping a timeline of clinical changes.
Jarnes Utz JR; Kim S; King K; Ziegler R; Schema L; Redtree ES; Whitley CB
Mol Genet Metab; 2017 Jun; 121(2):170-179. PubMed ID: 28476546
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.
Utz JR; Crutcher T; Schneider J; Sorgen P; Whitley CB
Mol Genet Metab; 2015 Feb; 114(2):274-80. PubMed ID: 25557439
[TBL] [Abstract][Full Text] [Related]
6. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Laboratory Profile of Gangliosidosis from Southern Part of India.
Gowda VK; Gupta P; Bharathi NK; Bhat M; Shivappa SK; Benakappa N
J Pediatr Genet; 2022 Mar; 11(1):34-41. PubMed ID: 35186388
[TBL] [Abstract][Full Text] [Related]
9. Neurophysiological investigations in GM1 and GM2 gangliosidoses.
Pampiglione G; Harden A
Neuropediatrics; 1984 Sep; 15 Suppl():74-84. PubMed ID: 6100798
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of Onset.
Kern J; Böhringer J; Timmann D; Trollmann R; Stendel C; Kamm C; Röbl M; Santhanakumaran V; Groeschel S; Beck-Wödl S; Göricke S; Krägeloh-Mann I; Synofzik M
Neurology; 2024 Jan; 102(1):e207898. PubMed ID: 38165373
[TBL] [Abstract][Full Text] [Related]
11. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
Tsuji D; Akeboshi H; Matsuoka K; Yasuoka H; Miyasaki E; Kasahara Y; Kawashima I; Chiba Y; Jigami Y; Taki T; Sakuraba H; Itoh K
Ann Neurol; 2011 Apr; 69(4):691-701. PubMed ID: 21520232
[TBL] [Abstract][Full Text] [Related]
12. Chitotriosidase as a biomarker for gangliosidoses.
Kim S; Whitley CB; Jarnes JR
Mol Genet Metab Rep; 2021 Dec; 29():100803. PubMed ID: 34646735
[TBL] [Abstract][Full Text] [Related]
13. Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients.
Welford RWD; Farine H; Steiner M; Garzotti M; Dobrenis K; Sievers C; Strasser DS; Amraoui Y; Groenen PMA; Giugliani R; Mengel E
Mol Genet Metab Rep; 2022 Mar; 30():100843. PubMed ID: 35242574
[TBL] [Abstract][Full Text] [Related]
14. Gangliosidoses.
Patterson MC
Handb Clin Neurol; 2013; 113():1707-8. PubMed ID: 23622392
[TBL] [Abstract][Full Text] [Related]
15. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
Kissell J; Rochmann C; Minini P; Eichler F; Stephen CD; Lau H; Toro C; Johnston JM; Krupnick R; Hamed A; Cox GF
Mol Genet Metab; 2024 Jul; 142(3):108512. PubMed ID: 38870773
[TBL] [Abstract][Full Text] [Related]
17. High-resolution loading tests in the study of genetic heterogeneity in gangliosidosis fibroblasts.
Akhunov VS; Mirenburg TV; Krasnopolskaya XD
J Inherit Metab Dis; 1994; 17(1):104-11. PubMed ID: 8051915
[TBL] [Abstract][Full Text] [Related]
18. Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses.
Hall P; Minnich S; Teigen C; Raymond K
Curr Protoc Hum Genet; 2014 Oct; 83():17.16.1-8. PubMed ID: 25271840
[TBL] [Abstract][Full Text] [Related]
19. L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
Castejón-Vega B; Rubio A; Pérez-Pulido AJ; Quiles JL; Lane JD; Fernández-Domínguez B; Cachón-González MB; Martín-Ruiz C; Sanz A; Cox TM; Alcocer-Gómez E; Cordero MD
Cells; 2021 Nov; 10(11):. PubMed ID: 34831346
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis.
Lee JS; Choi JM; Lee M; Kim SY; Lee S; Lim BC; Cheon JE; Kim IO; Kim KJ; Choi M; Seong MW; Chae JH
Brain Dev; 2018 May; 40(5):383-390. PubMed ID: 29439846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
